Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.
Identifieur interne : 002032 ( Main/Exploration ); précédent : 002031; suivant : 002033Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.
Auteurs : A. Lipton [États-Unis] ; K. Fizazi [France] ; A T Stopeck [États-Unis] ; D H Henry [États-Unis] ; M R Smith [États-Unis] ; N. Shore [États-Unis] ; M. Martin [Espagne] ; S. Vadhan-Raj [États-Unis] ; J E Brown [Royaume-Uni] ; G E Richardson [Australie] ; F. Saad [Canada] ; D A Yardley [États-Unis] ; K. Zhou [États-Unis] ; A. Balakumaran [États-Unis] ; A. Braun [États-Unis]Source :
- European journal of cancer (Oxford, England : 1990) [ 1879-0852 ] ; 2016.
Descripteurs français
- KwdFr :
- Administration par voie cutanée, Agents de maintien de la densité osseuse (administration et posologie), Diphosphonates (administration et posologie), Dénosumab (administration et posologie), Femelle, Humains, Imidazoles (administration et posologie), Maladies osseuses (), Mâle, Perfusions veineuses, Résultat thérapeutique, Tumeurs osseuses (secondaire), Tumeurs osseuses (traitement médicamenteux).
- MESH :
- administration et posologie : Agents de maintien de la densité osseuse, Diphosphonates, Dénosumab, Imidazoles.
- secondaire : Tumeurs osseuses.
- traitement médicamenteux : Tumeurs osseuses.
- Administration par voie cutanée, Femelle, Humains, Maladies osseuses, Mâle, Perfusions veineuses, Résultat thérapeutique.
English descriptors
- KwdEn :
- Administration, Cutaneous, Bone Density Conservation Agents (administration & dosage), Bone Diseases (prevention & control), Bone Neoplasms (drug therapy), Bone Neoplasms (secondary), Denosumab (administration & dosage), Diphosphonates (administration & dosage), Female, Humans, Imidazoles (administration & dosage), Infusions, Intravenous, Male, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Bone Density Conservation Agents, Denosumab, Diphosphonates, Imidazoles.
- drug therapy : Bone Neoplasms.
- prevention & control : Bone Diseases.
- secondary : Bone Neoplasms.
- Administration, Cutaneous, Female, Humans, Infusions, Intravenous, Male, Treatment Outcome.
Abstract
Analyses of phase III trials showed that denosumab was superior to zoledronic acid (ZA) in preventing skeletal-related events (SREs) irrespective of age, history of SREs, or baseline pain status. This analysis assessed the risk of SREs across additional baseline characteristics.
DOI: 10.1016/j.ejca.2015.09.011
PubMed: 26693901
Affiliations:
- Australie, Canada, Espagne, France, Royaume-Uni, États-Unis
- Communauté de Madrid, Massachusetts, Pennsylvanie, Québec, Texas, Victoria (État)
- Boston, Houston, Madrid, Melbourne, Montréal, Philadelphie, University Park (Pennsylvanie)
- Université d'État de Pennsylvanie
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002393
- to stream PubMed, to step Curation: 002347
- to stream PubMed, to step Checkpoint: 002347
- to stream Ncbi, to step Merge: 002F04
- to stream Ncbi, to step Curation: 002F04
- to stream Ncbi, to step Checkpoint: 002F04
- to stream Main, to step Merge: 002031
- to stream Main, to step Curation: 002032
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.</title><author><name sortKey="Lipton, A" sort="Lipton, A" uniqKey="Lipton A" first="A" last="Lipton">A. Lipton</name><affiliation wicri:level="4"><nlm:affiliation>Division of Oncology, Pennsylvania State University, Milton S. Hershey Medical Center, Hershey, USA. Electronic address: alipton@hmc.psu.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Oncology, Pennsylvania State University, Milton S. Hershey Medical Center, Hershey</wicri:regionArea><orgName type="university">Université d'État de Pennsylvanie</orgName><placeName><settlement type="city">University Park (Pennsylvanie)</settlement><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Fizazi, K" sort="Fizazi, K" uniqKey="Fizazi K" first="K" last="Fizazi">K. Fizazi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Institut Gustave Roussy, University of Paris Sud, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, Institut Gustave Roussy, University of Paris Sud, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Stopeck, A T" sort="Stopeck, A T" uniqKey="Stopeck A" first="A T" last="Stopeck">A T Stopeck</name><affiliation wicri:level="1"><nlm:affiliation>Stony Brook Cancer Center, Stony Brook, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Stony Brook Cancer Center, Stony Brook</wicri:regionArea><wicri:noRegion>Stony Brook</wicri:noRegion></affiliation></author><author><name sortKey="Henry, D H" sort="Henry, D H" uniqKey="Henry D" first="D H" last="Henry">D H Henry</name><affiliation wicri:level="3"><nlm:affiliation>Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia</wicri:regionArea><placeName><settlement type="city">Philadelphie</settlement><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Smith, M R" sort="Smith, M R" uniqKey="Smith M" first="M R" last="Smith">M R Smith</name><affiliation wicri:level="3"><nlm:affiliation>Division of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Boston, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Boston</wicri:regionArea><placeName><settlement type="city">Boston</settlement><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Shore, N" sort="Shore, N" uniqKey="Shore N" first="N" last="Shore">N. Shore</name><affiliation wicri:level="1"><nlm:affiliation>Carolina Urologic Research Center, Myrtle Beach, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Carolina Urologic Research Center, Myrtle Beach</wicri:regionArea><wicri:noRegion>Myrtle Beach</wicri:noRegion></affiliation></author><author><name sortKey="Martin, M" sort="Martin, M" uniqKey="Martin M" first="M" last="Martin">M. Martin</name><affiliation wicri:level="3"><nlm:affiliation>Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Vadhan Raj, S" sort="Vadhan Raj, S" uniqKey="Vadhan Raj S" first="S" last="Vadhan-Raj">S. Vadhan-Raj</name><affiliation wicri:level="3"><nlm:affiliation>Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston</wicri:regionArea><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Brown, J E" sort="Brown, J E" uniqKey="Brown J" first="J E" last="Brown">J E Brown</name><affiliation wicri:level="1"><nlm:affiliation>Academic Unit of Clinical Oncology, University of Sheffield, Weston Park Hospital, Sheffield, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Academic Unit of Clinical Oncology, University of Sheffield, Weston Park Hospital, Sheffield</wicri:regionArea><wicri:noRegion>Sheffield</wicri:noRegion></affiliation></author><author><name sortKey="Richardson, G E" sort="Richardson, G E" uniqKey="Richardson G" first="G E" last="Richardson">G E Richardson</name><affiliation wicri:level="3"><nlm:affiliation>Cabrini Medical Centre, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cabrini Medical Centre, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Saad, F" sort="Saad, F" uniqKey="Saad F" first="F" last="Saad">F. Saad</name><affiliation wicri:level="3"><nlm:affiliation>Departments of Surgery and Urology, University of Montreal Hospital Center, Montreal, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Departments of Surgery and Urology, University of Montreal Hospital Center, Montreal</wicri:regionArea><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Yardley, D A" sort="Yardley, D A" uniqKey="Yardley D" first="D A" last="Yardley">D A Yardley</name><affiliation wicri:level="1"><nlm:affiliation>Sarah Cannon Research Institute and Tennessee Oncology, Nashville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Sarah Cannon Research Institute and Tennessee Oncology, Nashville</wicri:regionArea><wicri:noRegion>Nashville</wicri:noRegion></affiliation></author><author><name sortKey="Zhou, K" sort="Zhou, K" uniqKey="Zhou K" first="K" last="Zhou">K. Zhou</name><affiliation wicri:level="1"><nlm:affiliation>Hematology/Oncology, Amgen Inc., Thousand Oaks, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hematology/Oncology, Amgen Inc., Thousand Oaks</wicri:regionArea><wicri:noRegion>Thousand Oaks</wicri:noRegion></affiliation></author><author><name sortKey="Balakumaran, A" sort="Balakumaran, A" uniqKey="Balakumaran A" first="A" last="Balakumaran">A. Balakumaran</name><affiliation wicri:level="1"><nlm:affiliation>Hematology/Oncology, Amgen Inc., Thousand Oaks, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hematology/Oncology, Amgen Inc., Thousand Oaks</wicri:regionArea><wicri:noRegion>Thousand Oaks</wicri:noRegion></affiliation></author><author><name sortKey="Braun, A" sort="Braun, A" uniqKey="Braun A" first="A" last="Braun">A. Braun</name><affiliation wicri:level="1"><nlm:affiliation>Hematology/Oncology, Amgen Inc., Thousand Oaks, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hematology/Oncology, Amgen Inc., Thousand Oaks</wicri:regionArea><wicri:noRegion>Thousand Oaks</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26693901</idno><idno type="pmid">26693901</idno><idno type="doi">10.1016/j.ejca.2015.09.011</idno><idno type="wicri:Area/PubMed/Corpus">002393</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002393</idno><idno type="wicri:Area/PubMed/Curation">002347</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002347</idno><idno type="wicri:Area/PubMed/Checkpoint">002347</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002347</idno><idno type="wicri:Area/Ncbi/Merge">002F04</idno><idno type="wicri:Area/Ncbi/Curation">002F04</idno><idno type="wicri:Area/Ncbi/Checkpoint">002F04</idno><idno type="wicri:Area/Main/Merge">002031</idno><idno type="wicri:Area/Main/Curation">002032</idno><idno type="wicri:Area/Main/Exploration">002032</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.</title><author><name sortKey="Lipton, A" sort="Lipton, A" uniqKey="Lipton A" first="A" last="Lipton">A. Lipton</name><affiliation wicri:level="4"><nlm:affiliation>Division of Oncology, Pennsylvania State University, Milton S. Hershey Medical Center, Hershey, USA. Electronic address: alipton@hmc.psu.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Oncology, Pennsylvania State University, Milton S. Hershey Medical Center, Hershey</wicri:regionArea><orgName type="university">Université d'État de Pennsylvanie</orgName><placeName><settlement type="city">University Park (Pennsylvanie)</settlement><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Fizazi, K" sort="Fizazi, K" uniqKey="Fizazi K" first="K" last="Fizazi">K. Fizazi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Institut Gustave Roussy, University of Paris Sud, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, Institut Gustave Roussy, University of Paris Sud, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Stopeck, A T" sort="Stopeck, A T" uniqKey="Stopeck A" first="A T" last="Stopeck">A T Stopeck</name><affiliation wicri:level="1"><nlm:affiliation>Stony Brook Cancer Center, Stony Brook, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Stony Brook Cancer Center, Stony Brook</wicri:regionArea><wicri:noRegion>Stony Brook</wicri:noRegion></affiliation></author><author><name sortKey="Henry, D H" sort="Henry, D H" uniqKey="Henry D" first="D H" last="Henry">D H Henry</name><affiliation wicri:level="3"><nlm:affiliation>Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia</wicri:regionArea><placeName><settlement type="city">Philadelphie</settlement><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Smith, M R" sort="Smith, M R" uniqKey="Smith M" first="M R" last="Smith">M R Smith</name><affiliation wicri:level="3"><nlm:affiliation>Division of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Boston, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Boston</wicri:regionArea><placeName><settlement type="city">Boston</settlement><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Shore, N" sort="Shore, N" uniqKey="Shore N" first="N" last="Shore">N. Shore</name><affiliation wicri:level="1"><nlm:affiliation>Carolina Urologic Research Center, Myrtle Beach, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Carolina Urologic Research Center, Myrtle Beach</wicri:regionArea><wicri:noRegion>Myrtle Beach</wicri:noRegion></affiliation></author><author><name sortKey="Martin, M" sort="Martin, M" uniqKey="Martin M" first="M" last="Martin">M. Martin</name><affiliation wicri:level="3"><nlm:affiliation>Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Vadhan Raj, S" sort="Vadhan Raj, S" uniqKey="Vadhan Raj S" first="S" last="Vadhan-Raj">S. Vadhan-Raj</name><affiliation wicri:level="3"><nlm:affiliation>Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston</wicri:regionArea><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Brown, J E" sort="Brown, J E" uniqKey="Brown J" first="J E" last="Brown">J E Brown</name><affiliation wicri:level="1"><nlm:affiliation>Academic Unit of Clinical Oncology, University of Sheffield, Weston Park Hospital, Sheffield, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Academic Unit of Clinical Oncology, University of Sheffield, Weston Park Hospital, Sheffield</wicri:regionArea><wicri:noRegion>Sheffield</wicri:noRegion></affiliation></author><author><name sortKey="Richardson, G E" sort="Richardson, G E" uniqKey="Richardson G" first="G E" last="Richardson">G E Richardson</name><affiliation wicri:level="3"><nlm:affiliation>Cabrini Medical Centre, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cabrini Medical Centre, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Saad, F" sort="Saad, F" uniqKey="Saad F" first="F" last="Saad">F. Saad</name><affiliation wicri:level="3"><nlm:affiliation>Departments of Surgery and Urology, University of Montreal Hospital Center, Montreal, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Departments of Surgery and Urology, University of Montreal Hospital Center, Montreal</wicri:regionArea><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Yardley, D A" sort="Yardley, D A" uniqKey="Yardley D" first="D A" last="Yardley">D A Yardley</name><affiliation wicri:level="1"><nlm:affiliation>Sarah Cannon Research Institute and Tennessee Oncology, Nashville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Sarah Cannon Research Institute and Tennessee Oncology, Nashville</wicri:regionArea><wicri:noRegion>Nashville</wicri:noRegion></affiliation></author><author><name sortKey="Zhou, K" sort="Zhou, K" uniqKey="Zhou K" first="K" last="Zhou">K. Zhou</name><affiliation wicri:level="1"><nlm:affiliation>Hematology/Oncology, Amgen Inc., Thousand Oaks, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hematology/Oncology, Amgen Inc., Thousand Oaks</wicri:regionArea><wicri:noRegion>Thousand Oaks</wicri:noRegion></affiliation></author><author><name sortKey="Balakumaran, A" sort="Balakumaran, A" uniqKey="Balakumaran A" first="A" last="Balakumaran">A. Balakumaran</name><affiliation wicri:level="1"><nlm:affiliation>Hematology/Oncology, Amgen Inc., Thousand Oaks, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hematology/Oncology, Amgen Inc., Thousand Oaks</wicri:regionArea><wicri:noRegion>Thousand Oaks</wicri:noRegion></affiliation></author><author><name sortKey="Braun, A" sort="Braun, A" uniqKey="Braun A" first="A" last="Braun">A. Braun</name><affiliation wicri:level="1"><nlm:affiliation>Hematology/Oncology, Amgen Inc., Thousand Oaks, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hematology/Oncology, Amgen Inc., Thousand Oaks</wicri:regionArea><wicri:noRegion>Thousand Oaks</wicri:noRegion></affiliation></author></analytic><series><title level="j">European journal of cancer (Oxford, England : 1990)</title><idno type="eISSN">1879-0852</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Cutaneous</term><term>Bone Density Conservation Agents (administration & dosage)</term><term>Bone Diseases (prevention & control)</term><term>Bone Neoplasms (drug therapy)</term><term>Bone Neoplasms (secondary)</term><term>Denosumab (administration & dosage)</term><term>Diphosphonates (administration & dosage)</term><term>Female</term><term>Humans</term><term>Imidazoles (administration & dosage)</term><term>Infusions, Intravenous</term><term>Male</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie cutanée</term><term>Agents de maintien de la densité osseuse (administration et posologie)</term><term>Diphosphonates (administration et posologie)</term><term>Dénosumab (administration et posologie)</term><term>Femelle</term><term>Humains</term><term>Imidazoles (administration et posologie)</term><term>Maladies osseuses ()</term><term>Mâle</term><term>Perfusions veineuses</term><term>Résultat thérapeutique</term><term>Tumeurs osseuses (secondaire)</term><term>Tumeurs osseuses (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bone Density Conservation Agents</term><term>Denosumab</term><term>Diphosphonates</term><term>Imidazoles</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Agents de maintien de la densité osseuse</term><term>Diphosphonates</term><term>Dénosumab</term><term>Imidazoles</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Bone Neoplasms</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Bone Diseases</term></keywords><keywords scheme="MESH" qualifier="secondaire" xml:lang="fr"><term>Tumeurs osseuses</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Bone Neoplasms</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs osseuses</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Cutaneous</term><term>Female</term><term>Humans</term><term>Infusions, Intravenous</term><term>Male</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie cutanée</term><term>Femelle</term><term>Humains</term><term>Maladies osseuses</term><term>Mâle</term><term>Perfusions veineuses</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Analyses of phase III trials showed that denosumab was superior to zoledronic acid (ZA) in preventing skeletal-related events (SREs) irrespective of age, history of SREs, or baseline pain status. This analysis assessed the risk of SREs across additional baseline characteristics.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Canada</li><li>Espagne</li><li>France</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Communauté de Madrid</li><li>Massachusetts</li><li>Pennsylvanie</li><li>Québec</li><li>Texas</li><li>Victoria (État)</li></region><settlement><li>Boston</li><li>Houston</li><li>Madrid</li><li>Melbourne</li><li>Montréal</li><li>Philadelphie</li><li>University Park (Pennsylvanie)</li></settlement><orgName><li>Université d'État de Pennsylvanie</li></orgName></list><tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Lipton, A" sort="Lipton, A" uniqKey="Lipton A" first="A" last="Lipton">A. Lipton</name></region><name sortKey="Balakumaran, A" sort="Balakumaran, A" uniqKey="Balakumaran A" first="A" last="Balakumaran">A. Balakumaran</name><name sortKey="Braun, A" sort="Braun, A" uniqKey="Braun A" first="A" last="Braun">A. Braun</name><name sortKey="Henry, D H" sort="Henry, D H" uniqKey="Henry D" first="D H" last="Henry">D H Henry</name><name sortKey="Shore, N" sort="Shore, N" uniqKey="Shore N" first="N" last="Shore">N. Shore</name><name sortKey="Smith, M R" sort="Smith, M R" uniqKey="Smith M" first="M R" last="Smith">M R Smith</name><name sortKey="Stopeck, A T" sort="Stopeck, A T" uniqKey="Stopeck A" first="A T" last="Stopeck">A T Stopeck</name><name sortKey="Vadhan Raj, S" sort="Vadhan Raj, S" uniqKey="Vadhan Raj S" first="S" last="Vadhan-Raj">S. Vadhan-Raj</name><name sortKey="Yardley, D A" sort="Yardley, D A" uniqKey="Yardley D" first="D A" last="Yardley">D A Yardley</name><name sortKey="Zhou, K" sort="Zhou, K" uniqKey="Zhou K" first="K" last="Zhou">K. Zhou</name></country><country name="France"><noRegion><name sortKey="Fizazi, K" sort="Fizazi, K" uniqKey="Fizazi K" first="K" last="Fizazi">K. Fizazi</name></noRegion></country><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Martin, M" sort="Martin, M" uniqKey="Martin M" first="M" last="Martin">M. Martin</name></region></country><country name="Royaume-Uni"><noRegion><name sortKey="Brown, J E" sort="Brown, J E" uniqKey="Brown J" first="J E" last="Brown">J E Brown</name></noRegion></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Richardson, G E" sort="Richardson, G E" uniqKey="Richardson G" first="G E" last="Richardson">G E Richardson</name></region></country><country name="Canada"><region name="Québec"><name sortKey="Saad, F" sort="Saad, F" uniqKey="Saad F" first="F" last="Saad">F. Saad</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002032 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002032 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26693901
|texte= Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26693901" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |